Your session is about to expire
← Back to Search
Hyperpolarized 13C Pyruvate Imaging for Glioblastoma
Study Summary
This trial is testing whether a new type of MRI that can show how well various types of treatment work will be useful to patients with glioblastoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is good, with creatinine levels below 1.5 mg/dL.My gender or race does not affect my eligibility for this study.I am 18 or older and expected to live at least 16 more weeks.I don't have any severe illnesses that can't be managed and that would affect my ability to undergo imaging tests safely.I am receiving standard treatment for my recurring brain tumor.My heart functions well without significant limitations.I am newly diagnosed with GBM and starting treatment with RT and TMZ.I haven't had a heart attack or unstable chest pain in the last year.I am having surgery for my returning brain tumor.I am able to care for myself but cannot do normal activities or work.I have no cancer history except for non-melanoma skin cancer or cervical carcinoma in-situ, or I've been cancer-free and off treatment for 3 years.
- Group 1: Cohort 1: Newly Diagnosed- Standard Treatment
- Group 2: Cohort 2: Recurrent- Standard Surgical Resection
- Group 3: Cohort 3: Recurrent- Standard Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment have any vacancies for participants?
"As indicated on clinicaltrials.gov, this medical trial is still looking for participants to enrol in the study. The investigation was originally posted on November 19th 2019 and last altered on December 14th 2021."
What is the extent of participation for this clinical experiment?
"Affirmative. According to clinicaltrials.gov, this study is currently recruiting patients with a first posting date of November 19th 2019 and most recent update on December 14th 2021. A total of 90 participants need to be recruited from 1 clinical trial site."
Has the Federal Drug Administration sanctioned Hyperpolarized 13C Pyruvate for therapeutic use?
"The safety of Hyperpolarized 13C Pyruvate has been given a score 1, as this is considered to be an early stage trial and little data exists which demonstrates its efficacy or safety."
Share this study with friends
Copy Link
Messenger